The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Open accessAbstract
Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions through an anchored transmembrane molecule and a soluble circulating protein.Both membrane-associated and soluble DPP4 exert catalytic activity, cleaving proteins containing a position 2 alanine or proline.DPP4-mediated enzymatic cleavage alternatively inactivates peptides or generates new bioactive moieties that may exert competing or novel activities.The widespread use of selective DPP4 inhibitors for the treatment of type 2 diabetes has heightened interest in the molecular mechanisms through which DPP4 inhibitors exert their pleiotropic actions.Here we review the biology of DPP4 with a focus on: 1) identification of pharmacological vs physiological DPP4 substrates; and 2) elucidation of mechanisms of actions of DPP4 in studies employing genetic elimination or chemical reduction of DPP4 activity.We review data identifying the roles of key DPP4 substrates in transducing the glucoregulatory, anti-inflammatory, and cardiometabolic actions of DPP4 inhibitors in both preclinical and clinical studies.Finally, we highlight experimental pitfalls and technical challenges encountered in studies designed to understand the mechanisms of action and downstream targets activated by inhibition of DPP4.(Endocrine Reviews 35: 992-1019, 2014) I. Introduction II.Molecular Biology of DPP4 A. Discovery, genomic organization, and superfamily of related enzymes B. Molecular function C. Regulation of DPP4 expression D. Post-translational modifications of DPP4 III.DPP4 Substrates A. Brain natriuretic peptide (BNP) B. Erythropoietin C. Eotaxin D. Gastrin-releasing peptide (GRP) E. Glucagon F. Glucagon-like peptide-1 (GLP-1) G. Glucagon-like peptide-2 (GLP-2) H. Glucose-dependent insulinotropic polypeptide (GIP) I. Granulocyte colony-stimulating factor (G-CSF) J. Granulocyte-macrophage CSF (GM-CSF) K. GHRH and IGF-1 L. High-mobility group box 1 (HMGB1) M. Macrophage-derived chemokine (MDC) N. Macrophage inflammatory protein-1 ␣ (MIP-1 ␣), chemokine (C-C motif) ligand 3-like 1 (CCL3L1), or LD78 O. Oxyntomodulin P. Pituitary adenylate cyclase-activating polypeptide (PACAP) Q. Neuropeptide Y (NPY) R. Peptide tyrosine tyrosine (PYY) S. Regulated on activation, normal T cell expressed and secreted (Rantes) T. Stromal cell-derived factor-1 (SDF-1) U. Substance P (SP) IV.Discovery of DPP4 as a Drug Target A. Selective DPP4 inhibitors, glucoregulatory substrates, and the treatment of type 2 diabetes B. Metabolic phenotypes in animal models of DPP4 deficiency V. Mechanism(s) of Action of DPP4 Inhibitors A. Selectivity of DPP4 inhibitors B. Mechanisms through which DPP4 inhibitors lower glucose C. Proof of concept and mechanisms for DPP4-dependent glucose control in humans
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Ramírez, G., Morrison, A. D., & Bittle, P. A. (2013) · Endocrine Practice · doi:10.4158/ep12306.ra · Cited by 34
Structure of the mouse dipeptidyl peptidase IV (CD26) gene
Bernard, A., Mattéi, M., Pierres, M., & Marguet, D. (1994) · Biochemistry · doi:10.1021/bi00254a032 · Cited by 33
Yamashita, K., Tachibana, Y., Matsuda, Y., Katunuma, N., Kochibe, N., & Kobata, A. (1988) · Biochemistry · doi:10.1021/bi00415a026 · Cited by 32
Okawada, M., Holst, J. J., & Teitelbaum, D. H. (2011) · Surgery · doi:10.1016/j.surg.2011.05.013 · Cited by 29
Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV
Hansen, L., Hare, K. J., Hartmann, B., Deacon, C. F., Ugleholdt, R., Plamboeck, A., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.08.012 · Cited by 26
Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?
Bhatt, D. L., & Cavender, M. A. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.05.005 · Cited by 26
Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys
Hoffmann, P., Bentley, P., Sahota, P. S., Schoenfeld, H. A., Martin, L., Longo, L., Spaet, R. H., Moulin, P., Pantano, S., Dubost, V., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623313516828 · Cited by 23
Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study
Kojima, Y., Kaga, H., Hayashi, S., Kitazawa, T., Iimura, Y., 大野, 誠., Yoshitsugu, M., Fujiwara, M., & Hiyoshi, T. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i1.8 · Cited by 21
Shlomo, S. B., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2353-7 · Cited by 19
Grouzmann, E., Bigliardi, P. L., Appenzeller, M., Pannatier, A., & Buclin, T. (2011) · Biological Chemistry · doi:10.1515/bc.2011.003 · Cited by 17
Faidley, T. D., Leiting, B., Pryor, K. D., Lyons, K., Hickey, G. J., & Thompson, D. R. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100811 · Cited by 17
van Poppel, P. C. M., Gresnigt, M. S., Smits, P., et al. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.039 · Cited by 15
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
Chen, X., Tang, H.-Y., Han, Y., Chien, C., Lin, C., Liu, H.-P., Huang, S.-F. K., Shyy, J., & Chiu, J. J. (2010) · International Journal of Biomedical Science · doi:10.59566/ijbs.2010.6301 · Cited by 15
A Peptidomics Strategy To Elucidate the Proteolytic Pathways That Inactivate Peptide Hormones
Tinoco, A. D., Kim, Y., Tagore, D. M., Wiwczar, J. M., Lane, W. S., Danial, N. N., & Saghatelian, A. (2011) · Biochemistry · doi:10.1021/bi2000033 · Cited by 14
Ben‐Shlomo, S., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2455-2 · Cited by 13
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Solun, B., Marcoviciu, D., & Dicker, D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0382-2 · Cited by 12
Hung, T., Wu, J., Liu, J., & Cheng, H. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07352.x · Cited by 9
Cited by
Adipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citationFluorogenic probes for disease-relevant enzymes
Zhang, J., Chai, X., He, X.-P., Kim, H.-J., Yoon, J., & Tian, H. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00907k · Cited by 606
Metadata
- Authors
- Mulvihill, E. E., & Drucker, D. J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2014-09-12
- Volume
- 35
- Issue
- 6
- Pages
- 992-1019
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2131821161
- Cited by
- 609
- References
- 217
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.